CALC Calcimedica announces FDA alignment on phase 2B trial Design for auxora in acute pancreatitis and identifies disease's first potential

CALC Calcimedica announces FDA alignment on phase 2B trial Design for auxora in acute pancreatitis and identifies disease's first potential registrational endpoints Calcimedica - FDA aligns on phase 2B primary endpoint of new-onset severe respiratory failure - Plans phase 1B trial for auxora in pah with data expected mid-2027 - Expects ind submission for cm5480 in mid-2027